Becton, Dickinson and Company Announces Executive Changes
April 28, 2021 at 06:50 am EDT
Share
BD (Becton, Dickinson and Company) announced the appointment of Elizabeth McCombs as executive vice president and chief technology officer, effective April 26, 2021, succeeding John DeFord. McCombs, 45, will be responsible for continuing to drive the company's category innovation strategy and leading all research and development (R&D) activities, including executing the current innovation pipeline and developing the future product portfolio. McCombs, who brings more than 20 years of extensive experience in advanced medical device innovation to her new role, joined BD in 2019 as the senior vice president of R&D for the BD Medical Segment. She was most recently, as vice president of R&D for Ethicon, while also leading China R&D and Industrial Design/Human Factors for all of J&J Medical Devices.
Becton, Dickinson and Company specializes in the development, manufacturing and marketing of medical and diagnostic equipment and materials. Net sales break down by family of products as follows:
- medical equipment (73.5%): surgical instruments, urological care products, pharmaceutical systems, etc.;
- diagnostic materials (18.7%): automated systems for blood testing, mycobacteria detection, and molecular biology, medical biology devices, etc.;
- clinical research and development tools (7.8%): tools for discovering drugs and vaccines, studying genes, culturing cells, and manipulating liquids, instruments for sorting and analyzing cells, monoclonal antibodies, etc.
Net sales are distributed geographically as follows: the United States (57.4%), Europe/Middle East/Africa (21.9%), Asia (15%) and other (5.7%).
BECTON, DICKINSON AND COMPANY 
